1993 Volume 13 Issue 3 Pages 234-240
The purpose of this study was to evaluate the therapeutic effects on human tumors in situ using 31P-MR spectroscopy (P-MRS). Sixteen patients with tumor were selected for this study. Seven had brain tumors,2 had metastatic brain tumors,2 had lung cancers,3 had liver tumors, and 2 had superficial malignant tumors. P-MRS was performed using a 2.0 Tesla MRI/S system (MRT-200/RX, Toshiba Co., Tokyo). The acquisition parameters were fixed during this series. P-MR spectra were normalized with total adenosine tri phosphates (ATP) and phosphocreatine (PCr), and these peak ratios were evaluated in relation to therapeutic effects. The therapeutic effects were assessed 1 to 6 months after therapy. In this study, these changes in peak ratios were characterized with regard to the follwing three points.1) In the complete response group (CR), PCr/ATP did not change, and PME/PCr and PDE/PCr were significantly decreased.2) In the progressive disease group (PD), PME/ATP and PDE/ATP were significantly increased.3) In the partial response group (PR) and no change group (NC), no significant changes were observed. These results showed that PME/ATP, PDE/ATP, PME/PCr and PDE/PCr ratios are sensitive indicators of therapeutic effects on tumors and may contribute to therapeutic planning. In particular, PME/PCr and PDE/PCr ratios were able to demonstrate tumor viability.
